BZBo-Yu Zhang

Bo-Yu Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bo-Yu Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Hailiang Li

    Ningxia Key Laboratory of Craniocerebral Diseases, Yinchuan, China

    1 shared publication
  • Haitao Ran

    Department of Ultrasound, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China; Chongqing Key Laboratory of Ultrasound Molecular Imaging and Therapy, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China

    1 shared publication
  • Haiyan Wang

    Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

    1 shared publication
  • Hong-Wan Dang

    Institute of Clinical Pharmacology and Department of Pharmacy, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China

    1 shared publication
  • Jing-Tao Wang

    School of Pharmaceutical Science, Southwest University, Chongqing, 40071, P. R. China

    1 shared publication
  • Li Hou

    Department of Otolaryngology, Head and Neck Surgery, General Hospital of Ningxia Medical University, Yin Chuan, P. R. China

    1 shared publication

Latest Publications

  • A nanosystem loaded with perfluorohexane and rose bengal coupled upconversion nanoparticles for multimodal imaging and synergetic chemo-photodynamic therapy of cancer

    by Hai-Yan Wang, Li Hou, Hai-Liang Li, Xu Wang, Yang Cao, Bo-Yu Zhang, Jing-Tao Wang, Shi-Jie Wei, Hong-Wan Dang, Hai-Tao Ran

    Theranostics is a new trend integrating diagnostic and therapeutic functions in tumour research. Theranostic nanoparticles enabling both tumour imaging and drug delivery are a promising platform for image-guided cancer therapy. Photodynamic therapy (PDT) has great potential in synergy with traditional chemotherapy but faces great challenges due to hypoxia, poor targeting ability and the limited penetration depth of visible light. To solve these problems, we presented a novel nanosystem of FA/UCNPs–RB/HCPT/PFH@lipid (denoted as FURH-PFH-NPs), with a perfluorohexane (PFH) carrying rich oxygen core and a folic acid-modified lipid shell. The shell contains 10-hydroxycamptothecin (HCPT) and self-fluorescing photosensitizer compounds, namely, upconversion nanoparticles and rose bengal (UCNPs–RB). In this study, FURH-PFH-NPs aggregated in SKOV3 cells (in vitro) and the nude xenograft tumour region when combined with folic acid receptors. When triggered by low-intensity focused ultrasound (LIFU), FURH-PFH-NPs released PFH, UCNPs–RB and HCPT. The above procedure was monitored through multimodal imaging, which simultaneously guided the tumour therapy. UCNPs–RB and PFH promoted the PDT effect under LIFU. Through PDT and HCPT, we obtained better therapeutic effects and good biosafety against SKOV3 nude xenograft tumours. FURH-PFH-NPs combined with LIFU and laser irradiation might be a promising strategy for ovarian cancer.